tbuckley/cabot-search huggingface dataset:
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
Authors: Matthew J. Frank, John H. Baird, Shabnum Patel, Juliana Craig, Jay Y. Spiegel, Zachary Ehlinger, Harshini Chinnasamy, Sheren F. Younes, Jean S. Oak, Yasodha Natkunam, Warren D. Reynolds, Maria Iglesias, Emma Crawford, Hrishikesh K. Srinagesh, Emily L. Egeler, Sally Arai, Laura J. Johnston, Robert Lowsky, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Surbhi Sidana, Wen-Kai Weng, Liora M. Schultz, Sneha Ramakrishna, Kara L. Davis, Bita Sahaf, Steven A. Feldman, Crystal L. Mackall, David B. Miklos, Lori Muffly
Journal: Blood (2021)
Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution
Authors: Kevin Wang, Maurizio Di Liberto, Yang Hu, Xiangao Huang, Rachel M Koldej, David Ritchie, Peter Martin, Giorgio Inghirami, Olivier Elemento, Constantine S. Tam, Selina Chen-Kiang
Journal: Blood (2021)
Abstract 9074: Cardiovascular Phenotypes Profiling for Congenitally Corrected Transposition of the Great Arteries and Its Prognosis Implication
Authors: Qiyu He, Huayan Shen, Zhou Zhou, Shoujun Li
Journal: Circulation (2021)

Introduction: Congenitally corrected transposition of the great arteries (ccTGA) is a rare and complex congenital heart disease with the characteristics of double discordance. Enormous accompanied anomalies are the culprit of difficult prognosis evaluation and clinical decisions. Hypothesis: To delineate a novel ccTGA clustering modality under HPO instruction and elucidate the relationship between phenotypes and prognosis in ccTGA patients. Methods: A retrospective review of 270 patients diagnosed with ccTGA in Fuwai hospital from 2009 to 2020 and cross-sectional follow-up was performed. Human Phenotype Ontology (HPO)-instructed clustering method was administered in ccTGA classification. Kaplan-Meier survival, Landmark analysis, and cox regression analysis were used to investigate the difference of outcomes between clusters with the combination of surgeries. Results: The median follow-up time was 4.29 (2.07-7.37) years. A total of three distinct phenotypic clusters were obtained after HPO-instructed classification with 21 in cluster 1, 136 in cluster 2, and 113 in cluster 3. Landmark analysis revealed significantly worse mid-term outcomes in all-cause mortality (p=0.042) and composite endpoints (p=0.008) of cluster 3 in comparison with cluster 1 and cluster 2. Multivariate analysis indicated that pulmonary arterial hypertension (PAH), atrioventricular septal defect (AVSD), and arrhythmia were risk factors for composite endpoints. Moreover, the surgical treatment was significantly different among the three groups (p&lt;0.001) and surgical strategies had different effects on the prognosis of the different phenotypic clusters. Conclusions: HPO-instructed clustering method delineates a novel image of ccTGA classification that might improve prognosis prediction and clinical decision.
Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis
Authors: Konstantinos C. Siontis, Pasquale Santangeli, Daniele Muser, Francis E. Marchlinski, Katja Zeppenfeld, Jarieke C. Hoogendoorn, Calambur Narasimhan, William H. Sauer, Matthew M. Zipse, Suraj Kapa, Vasanth Vedantham, David G. Rosenthal, Melissa R. Robinson, Kristen K. Patton, Francis Murgatroyd, Alexandru B. Chicos, Kyoko Soejima, Henri Roukoz, Frederic Sacher, Adarsh Bhan, Jason Appelbaum, Timm Dickfeld, Pranav Mankad, Kenneth A. Ellenbogen, Jordana Kron, Hyungjin Myra Kim, James Froehlich, Kim A. Eagle, Frank M. Bogun, Thomas C. Crawford
Journal: JAMA Cardiology (2021)

Ventricular tachycardia (VT) is associated with high mortality in patients with cardiac sarcoidosis (CS), and medical management of CS-associated VT is limited by high failure rates. The role of catheter ablation has been investigated in small, single-center studies.To investigate outcomes associated with VT ablation in patients with CS.This cohort study from the Cardiac Sarcoidosis Consortium registry (2003-2019) included 16 tertiary referral centers in the US, Europe, and Asia. A total of 158 consecutive patients with CS and VT were included (33% female; mean [SD] age, 52 [11] years; 53% with ejection fraction [EF] <50%).Catheter ablation of CS-associated VT and, as appropriate, medical treatment.Immediate and short-term outcomes included procedural success, elimination of VT storm, and reduction in defibrillator shocks. The primary long-term outcome was the composite of VT recurrence, heart transplant (HT), or death.Complete procedural success (no inducible VT postablation) was achieved in 85 patients (54%). Sixty-five patients (41%) had preablation VT storm that did not recur postablation in 53 (82%). Defibrillator shocks were significantly reduced from a median (IQR) of 2 (1-5) to 0 (0-0) in the 30 days before and after ablation (P < .001). During median (IQR) follow-up of 2.5 (1.1-4.9) years, 73 patients (46%) experienced VT recurrence and 81 (51%) experienced the composite primary outcome. One- and 2-year rates of survival free of VT recurrence, HT, or death were 60% and 52%, respectively. EF less than 50% and myocardial inflammation on preprocedural 18F-fluorodeoxyglucose positron emission tomography were significantly associated with adverse prognosis in multivariable analysis for the primary outcome (HR, 2.24; 95% CI, 1.37-3.64; P = .001 and HR, 2.93; 95% CI, 1.31-6.55; P = .009, respectively). History of hypertension was associated with a favorable long-term outcome (adjusted HR, 0.51; 95% CI, 0.28-0.92; P = .02).In this observational study of selected patients with CS and VT, catheter ablation was associated with reductions in defibrillator shocks and recurrent VT storm. Preablation LV dysfunction and myocardial inflammation were associated with adverse long-term prognosis. These data support the role of catheter ablation in conjunction with medical therapy in the management of CS-associated VT.
S100a8/S100a9-Emmprin-Vegfa Axis Initiated By <i>Tet2</i>-Deficient Immune Cells Exacerbates Lung Cancer Progression through Promotion of Angiogenesis
Authors: Yen T. M. Nguyen, Manabu Fujisawa, Tran B. Nguyen, Yasuhito Suehara, Tatsuhiro Sakamoto, Ryota Matsuoka, Yoshiaki Abe, Kota Fukumoto, Keiichiro Hattori, Masayuki Noguchi, Daisuke Matsubara, Shigeru Chiba, Mamiko Sakata-Yanagimoto
Journal: Blood (2021)
Development of Multi-Engineered iPSC-Derived CAR-NK Cells for the Treatment of B-Cell Malignancies
Authors: Luis Borges, Mark A Wallet, Chiamin-Liao Bullaughey, Michael F Naso, Buddha Gurung, Shelby Keating, Jill M Carton, John C Wheeler, Liam Campion, Mark Mendonca, Heidi K Jessup, Marilda Beqiri, Diana Chin, Hillary Millar Quinn, Barry A Morse
Journal: Blood (2021)
Success and continuous growth of the ERS clinical research collaborations
Authors: Maarten van den Berge, Céline Genton, Elise Heuvelin, Anita K. Simonds, Marc Humbert, Andre Nyberg, Reinoud Gosens, Louise Donnelly, Olivia Fulton, Marion Wilkens, Nicolas Roche, Christopher Brightling
Journal: European Respiratory Journal (2021)

<b>This editorial describes the ERS CRC programme, which addresses research areas across all major respiratory disease domains. It explains how the ERS Research Agency supports the CRCs to obtain external funding and ensures links with other ERS activities.</b>https://bit.ly/2WHIQPa
A reply letter on “A commentary on "Extracorporeal shockwave therapy improves pain and function in subjects with knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials" [Int. J. Surg. 2020; 82:64-75]”
Authors: Juan Avendaño- Coy, Natalia Comino-Suárez, Jesús Grande-Muñoz, Carlos Avendaño-López, Julio Gómez-Soriano
Journal: International Journal of Surgery (2021)
Acute Aortic Syndrome Revisited
Authors: Isidre Vilacosta, J Alberto San Román, Roberto di Bartolomeo, Kim Eagle, Anthony L Estrera, Carlos Ferrera, Shuichiro Kaji, Christoph A Nienaber, Vicenç Riambau, Hans-Joachim Schäfers, Francisco J Serrano, Jae-Kwan Song, Luis Maroto
Journal: Journal of the American College of Cardiology (2021)
Abstract 9485: Hypertension Risk Differs by Ethnicity in Young Asian Women Independent of Cardiometabolic Conditions
Authors: Jerry Liu, Kristine Gu, Malini Chandra, Lynn Guo, Nancy P Gordon, Joan C Lo
Journal: Circulation (2021)

Introduction: Prevalence of polycystic ovary syndrome (PCOS) and diabetes (DM), two cardiometabolic conditions (CMCs), vary by ethnicity in Asian women. Hypertension (HTN) also varies by ethnicity, but this has not been well studied in young Asian women with CMCs. We examined whether HTN diagnosis (Dx) in Asians varies by ethnicity, independent of body mass index (BMI), PCOS and DM. Methods: We used electronic health record data from a large US health plan to examine prevalence of HTN (≥2 Dx) in a cohort of 19,258 Chinese, 23,213 Filipina, and 19,108 South Asian women aged 21-44 years for whom BMI, PCOS (≥2 Dx) and DM (≥2 Dx + DM treatment) were ascertained. The associations of ethnicity and CMCs with HTN were examined using multivariable logistic regression. Results: Prevalence of HTN was 2% among Chinese and South Asian and 8% among Filipina women. Across all ethnic groups, compared to women with no CMCs, HTN prevalence was highest among those with DM and somewhat higher among those with PCOS and obesity. For all CMCs, Filipinas had the highest HTN prevalence (Figure). Adjusting for age, smoking, BMI, CMCs, and ethnicity, the odds of HTN were higher for Filipinas (2.6; CI 2.3-2.9) and slightly lower for South Asians (0.9; CI 0.7-0.98) compared to Chinese women; DM was associated with 4.7-fold higher odds (CI 4.1-5.3) and PCOS 1.4-fold higher odds (CI 1.1-1.8) of HTN. Conclusion: In young Asian women, DM, PCOS and obesity are associated with greater HTN burden. Compared to Chinese women, Filipinas have higher odds and South Asian women lower odds of HTN independent of BMI, PCOS, and DM. These data suggest a need for heightened BP surveillance in young Filipina women and Asian women with obesity or CMCs.
Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331
Authors: Ford, Mitchell, Cunningham, Farrugia, Hill, Rees, Calvert, Judson, Jackman
Journal: Clinical Cancer Research (2002)
Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase IIa CROSSWALK-c Trial Evaluating the Efficacy of Crovalimab As Adjunct Treatment in the Prevention of Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD)
Authors: Michael Callaghan, Kenneth I. Ataga, Lucia De Franceschi, Caterina Minniti, Nadiesh Balachandran, Diane-Charlotte Imbs, Thomas Perretti, Julia Ramos, Alexandre Sostelly, Pablo Bartolucci
Journal: Blood (2021)
Abstract 13090: Racial and Ethnic Differences in Anthracycline Cardiotoxicity
Authors: Lili Zhang, Justin Song, Rachel Clark, Arduino Mangoni, Ythan Goldberg, Leandro Slipczuk, Mario J Garcia, Neha Bansal, Diego B Sadler, Tomas Neilan, Roberto Alejandro Sica, Joseph A Sparano, Carlos J Rodriguez
Journal: Circulation (2021)

Background: There are limited data on anthracycline cardiotoxicity in racially and ethnically diverse populations. Therefore, our study sought to examine incident heart failure (HF) in cancer survivors treated with anthracycline in a multiracial community. Methods: We included consecutive adult patients who underwent anthracycline-based chemotherapy in 2016 and 2019 for any types of cancer at a single academic health system that serves a large multiracial community. Patients with preexisting HF were excluded. The end point was new development of clinical HF (ascertained by ICD-9 or 10 codes). Multivariable Cox proportional hazards models, adjusting for demographics, cardiovascular risk factors and anthracycline dose, were performed. Results: Our cohort studied 1,084 patients, including 21% Non-Hispanic White (NHW), 24% Non-Hispanic Blacks (NHB), 32% Hispanics and 2% Asians (Figure 1A). Mean age of the cohort was 58 ± 15 years, with 66% women. Hypertension, diabetes and hyperlipidemia were more prevalent in NHB, Hispanics and Asians than in NHW. Socioeconomic status score of NHB (-2.8 ± 2.7), Hispanics (-3.8 ± 2.8) and Asians (-2.0 ± 2.5) was significantly lower than NHW (0.1 ± 2.1, p&lt;0.001). Mean cumulative anthracycline dose was 321 ± 205mg/m 2 and it was similar across groups. During median follow-up of 15 months, 113 patients developed HF. The cumulative incidence of HF was 11% in the entire cohort, with 6% in NHW, 12% in NHB, 11% in Hispanics and 23% in Asians (Figure 1B, p=0.055). Asian race (HR 3.8, 95%CI 1.3-11.5, p=0.016) and increased age (HR 1.02, 95%CI 1.01- 1.04, p=0.023) were significantly associated with incident HF. NH Black (HR 1.5, 95%CI 0.8-3.1) and Hispanic (HR 1.3, 95%CI 0.7-2.7) groups did not reach significance in multivariable adjusted analysis. Conclusions: In a large cohort of multiracial cancer survivors treated anthracycline-based chemotherapy, a higher incidence of clinical HF was identified in NHB, Hispanics and Asians compared with NHW.
CD200R1 Distinguishes Uncommitted Precursors from Functionally Mature NK Cells within the Human Tonsil Stage 4A NK Cell Population
Authors: Youssef Youssef, Ansel P. Nalin, Jesse Kowalski, Megan Broughton, Matthew Lordo, Adam Gerhardt, Ekaterina Altynova, Apollinaire Ngankeu, David Clever, Benjamin Kramer, Anthony Mansour, Xiaoli Zhang, Christopher C. Oakes, James S. Blachly, Bradley W Blaser, Bethany L Mundy-Bosse, Aharon G. Freud
Journal: Blood (2021)
Treatment Shapes Clonal Evolution and Resistance Patterns in Murine <i>KMT2A</i>-Rearranged Leukemia with Subclonal <i>FLT3 N676K</i>
Authors: Ton Falqués, Mattias Pilheden, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Axel Hyrenius Wittsten, Julhash U. Kazi, Anna Hagstroem-Andersson
Journal: Blood (2021)
A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial
Authors: Mhairi Copland, Cono Ariti, Ian Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahidul Islam, Lars Kjeldsen, Alan K. Burnett, Robert Hills, Nigel H. Russell, Mike Dennis
Journal: Blood (2021)
Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease
Authors: Franck Mauvais-Jarvis, Carol A Lange, Ellis R Levin
Journal: Endocrine Reviews (2021)

Rapid effects of steroid hormones were discovered in the early 1950s, but the subject was dominated in the 1970s by discoveries of estradiol and progesterone stimulating protein synthesis. This led to the paradigm that steroid hormones regulate growth, differentiation, and metabolism via binding a receptor in the nucleus. It took 30 years to appreciate not only that some cellular functions arise solely from membrane-localized steroid receptor (SR) actions, but that rapid sex steroid signaling from membrane-localized SRs is a prerequisite for the phosphorylation, nuclear import, and potentiation of the transcriptional activity of nuclear SR counterparts. Here, we provide a review and update on the current state of knowledge of membrane-initiated estrogen (ER), androgen (AR) and progesterone (PR) receptor signaling, the mechanisms of membrane-associated SR potentiation of their nuclear SR homologues, and the importance of this membrane-nuclear SR collaboration in physiology and disease. We also highlight potential clinical implications of pathway-selective modulation of membrane-associated SR.
HIV Prevention Program Eligibility Among Adolescent Girls and Young Women — Namibia, 2019
Authors: Nickolas T. Agathis, Francis B. Annor, Rachel Coomer, Jennifer Hegle, Pragna Patel, Norbert Forster, Gabrielle O’Malley, Alison L. Ensminger, Rahimisa Kamuingona, Helena Andjamba, Molisa Manyando, Greta M. Massetti
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) relies on comprehensive and reliable population data to implement interventions to reduce HIV transmission in high-incidence areas among populations disproportionately affected by the HIV epidemic. Adolescent girls and young women in sub-Saharan Africa account for a disproportionate number of new HIV infections compared with their male peers (1). The DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) program includes multisectoral, layered interventions aimed at reducing factors that contribute to vulnerability to HIV infection among adolescent girls and young women in PEPFAR-supported sub-Saharan African countries (1). Namibia, a southern African country with a population of approximately 2.55 million among whom approximately 8% live with HIV infection, had their DREAMS program first implemented in 2017* (2,3). Data from the 2019 Namibia Violence Against Children and Youth Survey (VACS), the most recent and comprehensive nationally representative data source available to study the epidemiology of violence and other HIV risk factors, were used to estimate the percentage of adolescent girls and young women aged 13-24 years who would be eligible for DREAMS program services. The prevalence of individual DREAMS eligibility criteria, which comprise known age-specific risk factors associated with HIV acquisition, were estimated by age group. Among all adolescent girls and young women in Namibia, 62% were eligible for DREAMS based on meeting at least one criterion. Common eligibility criteria included adverse childhood experiences, specifically exposure to physical, emotional, and sexual violence and being an orphan;† and high-risk behaviors, such as early alcohol use,§ recent heavy alcohol use,¶ and infrequent condom use.** Using VACS data to estimate the prevalence of HIV risk factors and identify adolescent girls and young women at elevated risk for HIV acquisition in countries like Namibia with high HIV-incidence can inform programs and policies aimed at improving the well-being of these adolescent girls and young women and help control the HIV epidemics in these countries.
Accidental child poisoning
Authors: J. O'Donnell, F. D Brown, T. F Beattie, C. Newman, S. Smith, S. Cotton, D S Kettle
Journal: BMJ (1998)

How the cycle of poverty and ill health can be brokenEditor-To paraphrase a well known remark-wars are too serious to be entrusted to generals-public health, especially among poor people in developing countries and in the inner cities of industrialised countries, is too serious to be left to doctors and nurses alone.We say this quite deliberately as medical doctors on the staff of the World Health Organisation, of the Maryland department of health and mental hygiene, of universities, and of non-governmental organisations in Britain, Colombia, and Kenya.Our conviction is based on many years of work in the field in Africa, Asia, and Latin America, as well as in inner cities of the developed countries of Europe and North America.The number one health problem is poverty.For the poorest countries, the health sector alone cannot ensure better health even if it were able to function at maximum effectiveness.We have to accept that we can no longer deal with health while ignoring poverty.
Abstract 9305: Association of Silent Myocardial Infarction on Electrocardiogram and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis
Authors: Matthew J Singleton, Charles A German, Elsayed Z Soliman, Gregory L Burke, Joseph Yeboah
Journal: Circulation (2021)

Introduction: Silent myocardial infarction (SMI) on electrocardiogram (ECG) is associated with atherosclerotic cardiovascular disease, but the relationship between SMI on ECG and coronary artery calcium (CAC) remains poorly understood. Hypothesis: SMI on ECG is predictive of elevated CAC. Methods: Eligible participants from the Multi-Ethnic Study of Atherosclerosis (MESA) had ECG and CAC scoring at study enrollment (2000-2002). SMI was defined as ECG evidence of myocardial infarction in the absence of a history of clinical cardiovascular disease. CAC was modeled both continuously and categorically. The cross-sectional relationships between SMI on ECG and CAC were assessed using logistic regression and linear regression. Results: Among 6,705 eligible participants, 178 (2.7%) had baseline SMI. Compared to participants without SMI, those with SMI had higher CAC (median [IQR]: 61.2 [0 - 261.7] vs. 0 [0 - 81.5]; p &lt; 0.0001). Participants with SMI were more likely to have non-zero CAC (74% vs. 49%) and were more likely to have CAC ≥ 100 (40% vs. 23%). In a multivariable-adjusted logistic model, SMI was associated with higher odds of non-zero CAC (odds ratio 2.17, 95% CI 1.48 - 3.20, p &lt; 0.0001) and 51% higher odds of CAC ≥ 100 (odds ratio 1.51, 95% CI 1.06 - 2.16, p = 0.02). Conclusions: An incidental finding of SMI on ECG may serve to identify patients who have a higher odds of significant CAC and may benefit from additional risk-stratification to further refine their cardiovascular risk. Further exploration of the utility of CAC assessment in this patient population is needed.
Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas
Authors: Edith Julia, Sylvain Mareschal, Amel Chebel, Camille Golfier, Tony Andreas Müller, Camille Lours, Sofiane Hadj-Hamou, Nathalie Bissay, Manon Tschanz, Michele Ceribelli, Dimitri Chartoire, Aurélie Vernay, Sylvain Carras, David Sibon, Ambroise Marçais, Camille Laurent, Laurent Martin, Vahid Asnafi, Lea Payen, Damien Sanlaville, Claire Bardel-Danjean, Mikael Roussel, Vanessa Szablewski, Fanny Drieux, Philippe Ruminy, Marco Herling, Catherine Chassagne-Clément, Gilles Salles, Pierre Sujobert, Alexandra Traverse-Glehen, Lucile Baseggio, Laurence De Leval, Louis M. Staudt, Philippe Gaulard, Laurent Genestier, Emmanuel Bachy
Journal: Blood (2021)
二次予防のためのアテローム血栓性リスク層別化とエゼチミブ【Powered by NICT】
Authors: A Bohula Erin, A Morrow David, P Giugliano Robert, A Blazing Michael, He Ping, Park Jeong-Gun, A Murphy Sabina, A White Jennifer, Kesaniemi Y. Antero, R Pedersen Terje, J Brady Adrian, Mitchel Yale, P Cannon Christopher, Braunwald Eugene
Journal: Journal of the American College of Cardiology (2017)
Successful Outpatient Administration of Blinatumomab Infusion in Pediatric Patients with Acute Lymphoblastic Leukemia
Authors: Lora Bojilova-Dor, Kerice Pinkney, Brian Cauff, Deborah Kramer, Anne M Schaefer, Carmen Ballestas, Melissa H Diaz, Joan Spiro Stevens, Haley Grunwald, Ashley Siryk, Becky O'Neill, Maricel Pereira, Caroline Khalif, Caroline Moretti, Faina Shenderov, Iftikhar Hanif
Journal: Blood (2021)
ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma
Authors: Sammicheli Stefano, Camille Grandclement, Elie Dehilly, Maria Panagopoulou, Evangelia Martini, Rosa Castillo, Perrine Suere, Blandine Pouleau, Carole Estoppey, Julia Frei, Jeremy Loyau, Thierry Monney, Rebecca Wood, Amelie Croset, Alain Rubod, Girish Gudi, Venkatesha Udupa, Sunitha Gn, Vinu Menon, Daniel Rasmussen, Jeppe Koch Olsen, Roberto Giovannini, Aravind Chakrapani, Stanislas Blein, Marie-Agnes Doucey, Adam Drake, Alessandro Riva, Cyril Konto, Mario Perro, Lamine Mbow
Journal: Blood (2021)
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
Authors: Irene Manrique, Richard Greil, Johannes Andel, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Alexander Egle, Andreas Petzer, Niklas Zojer, Eberhard Gunsilius, Reinhard Ruckser, Boris Bozic, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Martin Schreder, Song-Yau Wang, Wolfgang Willenbacher, Maria-Theresa Krauth, Christoph Tinchon, Michael Fillitz, Thomas Melchardt, Stefan Knop, Bruno Paiva, Heinz Ludwig
Journal: Blood (2021)